Showing 3971-3980 of 6035 results for "".
- iVeena Submits IND Application to the FDA for Phase 2 Clinical Trial for Pediatric Myopiahttps://modernod.com/news/iveena-submits-ind-application-to-the-fda-for-phase-2-clinical-trial-for-pediatric-myopia/2482830/iVeena Delivery Systems announced the submission of an investigational new drug (IND) application to the FDA for IVMED-85 for the treatment of pediatric myopia. IVMED-85 is a new chemical entity (NCE), p
- CIRM Awards $4.7 Million for Vision Loss Gene Therapyhttps://modernod.com/news/cirm-awards-47-million-for-vision-loss-gene-therapy/2482827/The California Institute for Regenerative Medicine (CIRM) awarded $4.7 million to Blue Gen Therapeutics Foundation (Principal Investigator Aaron Nagiel, MD, PhD) to fund preclinical research that aims to develop a gene therapy for the rare disease blue cone monochromacy (BCM). <
- EssilorLuxottica to Acquire European Ophthalmology Network Optegra Clinicshttps://modernod.com/news/essilorluxottica-to-acquire-ophthalmology-network-optegra-clinics/2482825/EssilorLuxottica and MidEuropa have entered into an agreement in which EssilorLuxottica will acquire Optegra, an integrated ophthalmology platform operating in five European markets: the UK, Czech Republic, Poland, Slovakia and the Netherlands. Financial terms of the deal were
- University of Oklahoma Study Identifies 20 Novel Variants for Inherited Retinal Diseaseshttps://modernod.com/news/university-of-oklahoma-study-identifies-20-novel-variants-for-inherited-retinal-diseases/2482824/A new study out of the University of Oklahoma maps 20 new gene mutations contributing to rare inherited retinal diseases (IRDs). Researchers aim to use these findings to improve diagnostic accuracy and identify targets for future
- Alcon Receives FDA Approval of Tryptyr for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/alcon-receives-fda-approval-of-tryptyr-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2482823/Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of dry eye disease (DED). Tryptyr is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal senso
- Ocular Therapeutix To Close Enrollment this Week for SOL-R Trial Evaluating Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-to-close-enrollment-this-week-for-sol-r-trial-evaluating-axpaxli-in-wet-amd/2482822/Ocular Therapeutix announced that enrollment in the SOL-R registrational trial of its product candidate Axpaxli in wet age-related macular degeneration (AMD) will close this week. “Completing enrollment in SOL-R—the largest retinal TKI trial to date—one year
- Pangaea Data Secures Investment from Topcon Healthcare to Scale AI Platformhttps://modernod.com/news/pangaea-data-secures-investment-from-topcon-healthcare-to-scale-ai-platform/2482821/Pangaea Data announced an investment from Topcon Healthcare to accelerate the application of Pangaea’s AI platform, which aims to address care gaps in eye health and systemic disease. Financial terms of the deal were not disclosed.
- EyePoint Completes Enrollment in Phase 3 LUGANO Trial of Duravyu for Treatment of Wet AMDhttps://modernod.com/news/eyepoint-completes-enrollment-in-phase-3-lugano-trial-of-duravyu-for-treatment-of-wet-amd/2482820/EyePoint Pharmaceuticals announced it has enrolled and randomized over 400 patients in the phase 3 LUGANO pivotal trial of Duravyu for the treatment of wet age-related macular degeneration (AMD). Enrollment took 7 months. LUGANO is the first of two pivotal noninferiority trial
- NASA Astronauts to Headline Heidelberg Engineering’s 2025 International Spectralis Symposiumhttps://modernod.com/news/nasa-astronauts-to-headline-heidelberg-engineerings-2025-international-spectralis-symposium/2482818/Heidelberg Engineering announced that NASA astronauts Warren Hoburg and Tyson Brunstetter, OD, PhD, will lead the keynote presentation at the company’s
- Eylea 8 mg Approved in China for Wet AMDhttps://modernod.com/news/eylea-8-mg-approved-in-china-for-wet-amd/2482817/The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of wet age-related macular degeneration (AMD) in China. The approval is based on positive results from the phase 3 PULSAR trial a